Abstract 24P
Background
Lapatinib at an approved dose of 1250 to 1500 mg/day in Her2 positive metastatic breast cancer contributes to a high pill burden and financial toxicity. Hence the concept of “value meal” has been suggested, i.e. increasing the bioavailability by giving lower doses of lapatinib with meal, as suggested by phase I studies.
Methods
In our institution, for patients with Her2 positive metastatic breast cancer who cannot afford the approved dose of lapatinib or other Her2 agents, low dose or metronomic lapatinib, 500mg daily with meal, is offered. We conducted a retrospective review of the safety and efficacy of this regimen, including data from January 1, 2014 to December 31, 2020.
Results
A total of 47 females were enrolled. The majority had de novo metastatic disease (n=27,57.4%) and multiple visceral metastases (n=23,48.9%). The median number of lines of treatment before lapatinib was one. Lapatinib was given in combination, but 4 patients received it as a single agent. The disease control rate with lapatinib was 61.7%, out of whom 4.3% (n=2) experienced complete remission. The median progression free survival was 7 months (95% CI: 5.6 - 8.4 months), with a median overall survival of 12.5 months (95% CI: 9.7 - 15.3 months). The median duration of response was 4.5 months, ranging from 1.3 months to 45.8 months. The low-dose lapatinib was well-tolerated. Only eleven patients (23.4%) experienced some toxicity, with grade 3 in only one (2.1%) and no grade 4 toxicities. The most common toxicities were skin rashes and hand-foot syndrome. Dose interruptions were necessary in 3 (6.4%) patients, while drug was discontinued in one (2.1%).
Conclusions
The disease control rate and the progression free survival with low dose lapatinib is equivalent to the standard dose in published literature. The overall survival is short here as many did not receive any further anti-Her2 agents in view of financial toxicity. As a well tolerated regimen with less financial burden, this is an approach that needs further validation in larger randomised controlled trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Malabar Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
6P - Deep learning radiomics supports perioperative treatment decisions and is associated with LncRNAs in breast cancer: A multicenter study
Presenter: Yunfang Yu
Session: Poster viewing 01
7P - Predicting lymph node metastasis and molecular subtype from pathology united with genomics in breast cancer with multitask deep learning
Presenter: Zehua Wang
Session: Poster viewing 01
8P - Dismantling the role of liquid biopsy in predicting outcome of patients with early-stage breast cancer following neoadjuvant therapy: A systematic review
Presenter: Jeremiah Wijaya
Session: Poster viewing 01
9P - Development and validation of a pathogenomics model to improve the risk stratification of breast cancer: A deep learning study
Presenter: lin ruichong
Session: Poster viewing 01
10P - Enriched gut microbiota increases anticancer drug efficacy in breast cancer cell lines: A promising in vitro approach
Presenter: Selvaraj Jayaraman
Session: Poster viewing 01
11P - Preservation of intercostobrachial nerve during axillary lymph node dissection in breast cancer patients positively impacts chronic pain, sensory changes, and quality of life: Should it be the standard?
Presenter: Ajai Sasidhar
Session: Poster viewing 01
12P - Non-clinical factors influencing patient’s choice of mastectomy over breast conservation among Indian women with breast cancer
Presenter: Nivedita Sharma
Session: Poster viewing 01
13P - Hypofractionated radiotherapy in post operative breast cancer patients: 3-year clinical experience in a newly established cancer center
Presenter: Shaila Sharmin
Session: Poster viewing 01
14P - The impact of the deep inspiration breath-hold (DIBH) technique in the heart and other organ-at-risk (OAR) dose sparing in the postoperative radiotherapy to the left early breast cancer
Presenter: Hui-Ling Yeh
Session: Poster viewing 01
15P - Delays in breast cancer treatment in a tertiary hospital
Presenter: Rogelio Velasco
Session: Poster viewing 01